According to filings with the U.S. Securities and Exchange Commission, Incyclix Bio is raising up to $20,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Incyclix Bio
Incyclix Bio, LLC is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The companys lead compound is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.

To learn more about Incyclix Bio, visit https://incyclixbio.com/
Incyclix Bio Linkedin Page: https://www.linkedin.com/company/incyclix-bio-llc/

Contact:
Patrick Roberts, Chief Executive Officer
919-328-0003
https://www.linkedin.com/in/pjroberts77/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.